Big Pharma's on a roll these days along with the larger healthcare sector. With that in mind, here are two stocks to buy and two to sell in leading industries. More
-
Sponsored By:
-
Sponsored By:
-
Sponsored By:
ZTS
Recent Articles
Did Facebook Kill the Blockbuster IPO?
Social deals are all but dead, and overall IPO size just hasn't been the same. More
Should I Buy Pfizer? 3 Pros, 3 Cons
Pfizer's Q4 earnings put a small scare into investors a couple weeks back, but the pharma behemoth is built too well to ignore. More
Q1 in Review: The Top 3 IPO Trends
The first quarter's in the books and turned out to be a solid one for IPOs. Let's take a look at the three sectors that kicked off 2013 the strongest. More
3 Dow Jones Stocks to Buy
Investors would be wise to care less about the Dow Jones and more about its individual components -- namely, these three attractive blue chips. More
Bausch & Lomb Prepping to Go Public?
A report says private equity investor Warburg Pincus is interviewing investment banks about a potential Bausch & Lomb IPO. More
Top 10 Dow Dividend Stocks for February
Income investors could do a lot worse than buying into these venerable blue chips -- especially the stock that continues to hold the crown. More
